

BILBAO SPAIN

Midas Mulder



Bio

Midas Berend Mulder was born on the 11th of August 1989 in Enschede, the Netherlands. He studied Pharmacy at the University of Utrecht from 2009 – 2014. As part of his Master's degree, he performed a six-month research project at the University of Florida in Gainesville under the supervision of Prof. Dr. H. Derendorf. After his graduation in 2014, Midas started his career as a pharmacist in the clinical pharmacy at the Franciscus Gasthuis & Vlietland hospital in Rotterdam, the Netherlands. In 2015 Midas started his residency in clinical pharmacy at the Franciscus Gasthuis & Vlietland hospital and Erasmus University Medical Center in Rotterdam, the Netherlands, under the supervision of Dr. E.M.

Westerman and Prof. Dr. P.M.L.A. van den Bemt. Midas finished his residency in hospital pharmacy by the end of 2018. Afterwards, he started working as a clinical pharmacist at the Erasmus University Medical Center. In this hospital he specialized in the pharmaceutical care for complex gastrointestinal and Hepato Pancreato Biliary patients. Simultaneously he started as a PhD-student at the Department of Gastroenterology and Hepatology under the supervision of Prof. Dr. H.J. Metselaar focusing on the optimization of drug therapy for liver transplant recipients. He defended his PhD on the 5th of June 2024. Midas is currently working as a clinical pharmacist and deputy trainer of clinical pharmacy residents at the Haaglanden Medical Center in The Hague. In this hospital he is responsible for medication safety, medication reconciliation, educational activities and research.

Abstract

The global burden of cirrhosis is rising. Data suggest that the aetiology of cirrhosis in the United States of America and Europe is shifting from active hepatitis B and C virus infection towards resolved or treated viral hepatitis, alcohol consumption and metabolic dysfunction-associated fatty liver disease (MAFLD) due to the increasing numbers of overweighted and obese adults. Clinicians increasingly face the challenge of safely prescribing medicines for complications of hepatic disease and comorbidities. Prescribing in patients with cirrhosis is complicated by alterations that can occur in the pharmacology of medicines. In this talk an overview of the current knowledge on the pharmacokinetics and pharmacodynamics of medicines in patients with cirrhosis will be presented. Furthermore, an overview of the toxicological effects that patients with cirrhosis seem to be more susceptible to will be presented. Finally, approaches to improve medication safety in patients with cirrhosis in clinical practice will be shown.

